500257 logo

Lupin Stock Price

Symbol: BSE:500257Market Cap: ₹860.1bCategory: Pharmaceuticals & Biotech

500257 Share Price Performance

₹1,883.00
-63.95 (-3.28%)
15.6% undervalued intrinsic discount
₹2,230.43
Fair Value
₹1,883.00
-63.95 (-3.28%)
15.6% undervalued intrinsic discount
₹2,230.43
Fair Value
Price ₹1,883.00
AnalystConsensusTarget ₹2,230.43

500257 Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget·Updated
Fair Value ₹2.23k 15.6% undervalued intrinsic discount

Launching Injectable Products Like Liraglutide Will Strengthen Future Prospects

0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative

Community Fair Values

Recent 500257 News & Updates

No updates

Lupin Limited Key Details

₹227.1b

Revenue

₹73.8b

Cost of Revenue

₹153.3b

Gross Profit

₹120.5b

Other Expenses

₹32.8b

Earnings

Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 05, 2025
Earnings per share (EPS)
71.85
Gross Margin
67.50%
Net Profit Margin
14.45%
Debt/Equity Ratio
29.4%

Lupin Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About 500257

Founded
1968
Employees
24006
CEO
Vinita Gupta
WebsiteView website
www.lupin.com

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company also offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, women’s health, and central nervous system areas, as well as pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies. In addition, it focuses on various therapeutic spectrum, including rheumatology, oncology, neuroscience, and renal therapies. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consists of labs and collection centers. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Indian Market Performance

  • 7 Days: 0.2%
  • 3 Months: 5.2%
  • 1 Year: -2.4%
  • Year to Date: -1.1%
Over the last 7 days, the market has dropped 1.6%, driven by a pullback of 2.1% in the Financials sector. The market has dropped 6.5% in the last year. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading